Tokuyama (4043) AI Stock Analysis

• Market Cap: $270.40B
• Dividend Yield: 2.66%
• Average Volume (3M): 407.64K
• Price to Earnings (P/E): 12.9
• Beta (1Y): 0.89
• Revenue Growth: 0.81%
• EPS Growth: 0.23%
• Country: JP
• Employees: 5,734
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals - Specialty
• EPS (TTM): 100.54
• Shares Outstanding: 72,088,326
• 10 Day Avg. Volume: 395,260
• 30 Day Avg. Volume: 407,639
• PEG Ratio: 0.27
• Price to Book (P/B): 0.77
• Price to Sales (P/S): 0.58
• P/FCF Ratio: 6.74
• Enterprise Value/Market Cap: 0.97
• Enterprise Value/Revenue: 0.77
• Enterprise Value/Gross Profit: 2.41
• Enterprise Value/Ebitda: 5.33
• 1Y Price Target: $3,809.45
• Price Target Upside: -1.08% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 70 Neutral
• Price Target: ¥4,036.00 ▲(4.80% Upside)

Tokuyama's stock is supported by strong financial performance and a reasonable valuation, making it a solid choice in the specialty chemicals industry. Technical indicators show moderate strength, but the lack of recent earnings call data or corporate events limits further insights.

Tokuyama Business Overview & Revenue Model

Company Description

Tokuyama Corporation (4043) is a diversified Japanese company primarily engaged in the production and sale of a wide range of chemical products, including silicones, fine chemicals, and specialty materials. The company operates across several sectors, including semiconductors, pharmaceuticals, and construction materials, and is known for its innovative solutions and high-quality products tailored to meet the needs of various industries. Tokuyama also invests in advanced technologies and sustainability initiatives to enhance its product offerings and maintain competitive advantages in the market.

How the Company Makes Money

Tokuyama generates revenue through multiple streams, primarily from the sale of its chemical products and materials. Key revenue streams include the semiconductor materials division, which supplies silicon wafers and other related products; the pharmaceutical sector, which focuses on active pharmaceutical ingredients; and construction materials, which includes cement and other construction-related chemicals. The company also benefits from strategic partnerships with various technology firms and suppliers, enabling it to expand its market reach and enhance product development. Additionally, Tokuyama's commitment to research and development allows it to innovate and introduce new products, contributing to increased sales and market share.

Tokuyama Financial Statement Overview

Summary

Tokuyama demonstrates steady revenue growth and improved profitability, supported by effective cost management and stable cash flow generation. The balance sheet remains strong with controlled leverage and a robust equity base, while cash flows indicate efficient cash conversion despite some fluctuations. These factors contribute to a solid financial standing in the specialty chemicals industry.

Income Statement

Tokuyama's revenue showed a modest increase from 2024 to 2025, with a revenue growth rate of 0.32%. The gross profit margin improved to 31.52% in 2025, reflecting efficient cost management. The net profit margin increased to 6.82%, indicating enhanced profitability. The EBIT margin was 8.74%, and the EBITDA margin was 15.13%, both showing positive trends. Overall, the company demonstrates strong profitability with stable revenue growth.

Balance Sheet

The debt-to-equity ratio improved from 0.42 in 2024 to 0.42 in 2025, showing consistent leverage management. The return on equity (ROE) increased to 8.94%, indicating effective use of equity to generate profit. The equity ratio was 54.94%, reflecting a strong equity base. Overall, Tokuyama maintains a solid balance sheet with stable leverage and equity management.

Cash Flow

Tokuyama's free cash flow grew by 22.83%, showcasing strong cash-generating abilities. However, the operating cash flow to net income ratio decreased to 2.24, while the free cash flow to net income ratio remained stable at 1.27, indicating effective conversion of net income to cash flow. Overall, the cash flow statements reflect robust cash management, albeit with some variability in operating cash flow.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	342.38B	343.07B	341.99B	351.79B	293.83B	302.41B
Gross Profit	109.27B	108.14B	99.52B	90.78B	95.41B	95.15B
EBITDA	49.39B	51.91B	44.88B	36.79B	48.75B	49.49B
Net Income	20.90B	23.39B	17.75B	9.36B	28.00B	24.53B
Balance Sheet
Total Assets	474.44B	476.21B	457.36B	478.34B	433.21B	386.79B
Cash, Cash Equivalents and Short-Term Investments	79.84B	75.54B	48.68B	68.08B	83.12B	83.68B
Total Debt	111.74B	110.69B	105.78B	142.45B	109.22B	98.44B
Total Liabilities	197.73B	202.35B	197.41B	236.74B	200.29B	181.53B
Stockholders Equity	262.17B	261.56B	249.25B	229.45B	224.50B	198.56B
Cash Flow
Free Cash Flow	0.00	29.77B	24.24B	-43.72B	-5.90B	19.51B
Operating Cash Flow	0.00	52.37B	55.83B	-11.80B	25.99B	43.31B
Investing Cash Flow	0.00	-23.48B	-30.41B	-33.76B	-33.80B	-19.28B
Financing Cash Flow	0.00	-1.11B	-46.51B	30.15B	5.12B	-22.53B

Tokuyama Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3851.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4043, the sentiment is Positive. The current price of 3851 is above the 20-day moving average (MA) of 3719.65, above the 50-day MA of 3587.36, and above the 200-day MA of 2980.86, indicating a bullish trend. The MACD of 49.91 indicates Negative momentum. The RSI at 61.99 is Neutral, neither overbought nor oversold. The STOCH value of 59.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4043.

Tokuyama Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
4182	―	$555.40B	13.32	6.42%	3.50%	-6.27%	40.98%
4205	―	$324.29B	12.87	7.18%	4.21%	5.34%	-19.93%
4118	―	$265.98B	11.74	4.90%	3.56%	3.80%	-11.14%
4043	―	$270.40B	12.94	8.86%	2.66%	0.81%	0.23%
4046	―	¥212.32B	19.45	―	1.26%	1.18%	32.56%
Sector *	―	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
4208	―	$221.97B	11.14	-1.26%	4.88%	-0.53%	-117.46%

Tokuyama Corporate Events

Tokuyama Reports Q2 2025 Results and Consolidates New Acquisitions

Tokuyama Corporation reported a decrease in net sales for Q2 of fiscal 2025 despite strong semiconductor-related product sales, attributed to declining overseas vinyl chloride-related product prices. However, operating profit increased due to improved manufacturing costs. The acquisition of IVD and IVDM businesses was finalized, and these will be consolidated into Tokuyama’s operations from the second half of FY2025, impacting segment forecasts.

The most recent analyst rating on (JP:4043) stock is a Hold with a Yen4036.00 price target. To see the full list of analyst forecasts on Tokuyama stock, see the JP:4043 Stock Forecast page.

Tokuyama Corporation Reports Strong Profit Growth in Q2 Fiscal 2025

Tokuyama Corporation reported its consolidated financial results for the second quarter of fiscal 2025, showing a slight decline in net sales by 1.1% compared to the previous year. However, the company achieved significant growth in operating profit and ordinary profit, with increases of 37.2% and 39.2% respectively. The comprehensive income also saw a substantial rise of 69.8%. The company maintained its dividend forecast and noted changes in its scope of consolidation, adding A&T Suzhou Co., Ltd. and removing FL Tokuyama Corporation. These results indicate a strong operational performance despite a challenging market environment, potentially enhancing Tokuyama’s industry positioning and offering positive implications for stakeholders.

The most recent analyst rating on (JP:4043) stock is a Hold with a Yen4036.00 price target. To see the full list of analyst forecasts on Tokuyama stock, see the JP:4043 Stock Forecast page.

Tokuyama Completes Acquisition of JSR’s Diagnostic Business

Tokuyama Corporation has completed the acquisition of a newly established company that will take over JSR Corporation’s in vitro diagnostic pharmaceutical business. This strategic move involves the transfer of the business to a new subsidiary, Tokuyama Life Science Corporation, which will enhance Tokuyama’s capabilities in the diagnostics sector. The acquisition is expected to bolster Tokuyama’s market presence and operational capacity, although the financial impact is still being assessed.

The most recent analyst rating on (JP:4043) stock is a Buy with a Yen3800.00 price target. To see the full list of analyst forecasts on Tokuyama stock, see the JP:4043 Stock Forecast page.

Tokuyama Corporation Reports Mixed Q1 Fiscal 2025 Results

Tokuyama Corporation is a Japanese company primarily engaged in the manufacturing and sale of chemicals, cement, and electronic materials, with a focus on innovative solutions in the industrial sector.

Tokuyama Reports Q1 Fiscal 2025 Results Amid Market Challenges

Tokuyama Corporation reported a decrease in net sales for Q1 Fiscal 2025 despite strong semiconductor-related product sales, attributed to declining overseas chemical market prices. Operating profit saw an increase due to improved manufacturing costs, but growth was limited by inventory valuation losses. The company maintains its performance forecasts for the fiscal year, indicating stable business operations.

Tokuyama Reports Mixed Q1 Fiscal 2025 Results with Positive Dividend Outlook

Tokuyama Corporation reported its consolidated financial results for the first quarter of fiscal 2025, showing a slight decline in net sales by 0.8% compared to the previous year. Despite this, operating profit increased by 5.1%, although ordinary profit decreased by 9.8%. The company also announced a forecasted increase in annual dividends per share for fiscal 2025, indicating a positive outlook on future performance. Additionally, there were significant changes in the scope of consolidation, with the addition and reduction of certain subsidiaries.